SARS-CoV-2 (2019-nCoV) Antigen Reagents

SARS-CoV-2 (2019-nCoV, Novel Coronavirus 2019) has led to pneumonia (COVID-19) that sickened over 56.9M people worldwide. Same as all other coronaviruses, the genome of SARS-CoV-2 (2019-nCoV) encodes the spike protein, the envelope protein, the membrane protein, and the nucleocapsid protein.

The spike protein (S-protein) is the common target for neutralizing antibodies and vaccines. Spike protein contains two subunits, S1 and S2. S1 contains a receptor binding domain (RBD), which is responsible for recognizing and binding with the cell surface receptor. S2 subunit contains other basic elements needed for the membrane fusion. SARS-CoV-2 (2019-nCoV) (ref.) can infect the human respiratory epithelial cells through interaction with huamn ACE2. Indeed, the recombinant Spike protein can bind with recombinant ACE2 protein.

The Nucleocapsid Protein (N-protein) is the most abundant protein in coronavirus. The N-protein is a highly immunogenic phosphoprotein, and it is normally very conserved. The N protein of coronavirus is often used as a marker in diagnostic assays.

Sino Biological is the first company in the world to produce recombinant proteins of SARS-CoV-2. We launched the spike protein on Jan 22nd, only 12 days after the sequence is published. Till this day, Sino Biological has developed a large panel of reagents for COVID19 research. The available products include hundreds of antigens (the N protein, S protein, the S1 and S2 subunits of the S protein, and the RBD domain of the S proteins, Plpro, MTase, NSP3, NSP8，NSP9), monoclonal antibodies, ELISA kits, and expression vectors for SARS-CoV-2 and its receptor. These reagents have supported hundreds of research groups around the globe for their vaccine and antibody development works. Sino Biological is also offering pseudovirus-based infection assay services, allowing rapid screening of antibodies and compounds for neutralization potential.